Showing results (91-100 of 154) with videos related to
Sort By:
Pageof 16
Scientific Reports|February 22, 2020
Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trialTakeshi Morimoto, Ichiro Sakuma, Mio Sakuma, et al.Cardiovascular Diabetology|June 29, 2021
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trialAtsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.Cardiovascular Diabetology|August 1, 2021
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metforminAtsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.Scientific Reports|June 14, 2019
Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trialTakeshi Morimoto, Ichiro Sakuma, Mio Sakuma, et al.Journal of Atherosclerosis and Thrombosis|December 21, 2020
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin TherapyMasato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, et al.BMC Pulmonary Medicine|December 17, 2025
Screening for lung fibrosis using serum surfactant protein-D, KL-6, and a deep learning algorithm on chest radiographs: a prospective observational studyHirotaka Nishikiori, Naoya Yama, Kenichi Hirota, et al.BMJ Open|October 22, 2021
Experience and awareness of research integrity among Japanese physicians: a nationwide cross-sectional studyRie Nishimura, Jiro Takeuchi, Mio Sakuma, et al.Frontiers in Endocrinology|October 19, 2020
Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes MellitusMasato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, et al.Cardiovascular Diabetology|June 17, 2020
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapyMasato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|May 24, 2024
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trialAtsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.Pageof 16